Immunohistochemical analysis of PAI-2 (plasminogen activator inhibitor type 2) and p53 protein in early gastric cancer patients with recurrence: a preliminary report.
BACKGROUND
High levels of urokinase-type plasminogen activator (u-PA) were demonstrated in gastric carcinomas along with inhibitors of plasminogen activators (PAI-1 and PAI-2). They may influence the ability to invade and metastasize and therefore be of importance to the risk of recurrence of stomach neoplasms after curative operation. This also appears to be the case for p53 mutations and p53 protein overexpression.


METHODS
Six patients, all differentiated cancer cases who developed recurrent disease 5-10 years after curative operations for early gastric cancers (recurrence group), were studied in comparison with 49 patients who had no recurrence more than 10 years after similar surgery (control group). The expression of u-PA, PAI-1, PAI-2 and p53 was compared immunohistochemically in the recurrence and control groups.


RESULTS
The expression of PAI-2 was significantly more frequent in the recurrence group, being found in five (83.3%) patients vs eight (16.3%) in the control group. p53 was expressed in five (83.3%) patients in the recurrence group and in 15 (30.6%) in the control group; the rate was again significantly higher in the former.


CONCLUSIONS
The results suggest that PAI-2 and p53 expressed in differentiated early gastric cancers are possible indices of the risk of recurrence.
Kammori
M
M
Department of Surgery, University of Tokyo Branch Hospital, Japan. kammori-dis@h.u-tokyo.ac.jp
Kaminishi
M
M
Kobayashi
K
K
Oohara
T
T
Endo
H
H
Takubo
K
K
Hashimoto
H
H
D000230:Adenocarcinoma / Q000737:chemistry* / Q000556:secondary; D000368:Aged; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008113:Liver Neoplasms / Q000737:chemistry / Q000556:secondary; D008175:Lung Neoplasms / Q000737:chemistry / Q000556:secondary; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D010534:Peritoneal Neoplasms / Q000737:chemistry / Q000556:secondary; D017396:Plasminogen Activator Inhibitor 2 / Q000032:analysis*; D012306:Risk; D013274:Stomach Neoplasms / Q000737:chemistry* / Q000473:pathology; D016159:Tumor Suppressor Protein p53 / Q000032:analysis*; D014568:Urokinase-Type Plasminogen Activator / Q000032:analysis
D017396:Plasminogen Activator Inhibitor 2; D016159:Tumor Suppressor Protein p53; D014568:Urokinase-Type Plasminogen Activator